Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

This Review describes the rates and mechanisms of common toxic renal effects of antiretroviral therapies, with particular emphasis on tenofovir, and outlines strategies for preventing acute and ...